This company has been acquired
Augmedix Future Growth
Future criteria checks 2/6
Augmedix's earnings are forecast to decline at 0.9% per annum while its annual revenue is expected to grow at 20.6% per year. EPS is expected to grow by 2.6% per annum.
Key information
-0.9%
Earnings growth rate
2.6%
EPS growth rate
| Healthcare Services earnings growth | 32.4% |
| Revenue growth rate | 20.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 02 Oct 2024 |
Recent future growth updates
Recent updates
Augmedix, Inc. (NASDAQ:AUGX) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jun 19
Is Augmedix, Inc. (NASDAQ:AUGX) Trading At A 40% Discount?
May 21Augmedix, Inc. (NASDAQ:AUGX) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
Apr 25Augmedix: Secular AI Tailwinds, But Still Unattractive Risk-Reward
Mar 24Augmedix, Inc. (NASDAQ:AUGX) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 09Augmedix reports Q2 results
Aug 08Augmedix: A Splendid Long-Term Investing Opportunity
Jan 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 69 | -25 | N/A | N/A | 2 |
| 12/31/2024 | 53 | -30 | N/A | N/A | 2 |
| 6/30/2024 | 52 | -24 | -18 | -15 | N/A |
| 3/31/2024 | 49 | -20 | -21 | -17 | N/A |
| 12/31/2023 | 45 | -19 | -19 | -15 | N/A |
| 9/30/2023 | 41 | -20 | -21 | -19 | N/A |
| 6/30/2023 | 37 | -21 | -22 | -20 | N/A |
| 3/31/2023 | 34 | -24 | -20 | -19 | N/A |
| 12/31/2022 | 31 | -24 | -18 | -17 | N/A |
| 9/30/2022 | 29 | -24 | -19 | -18 | N/A |
| 6/30/2022 | 27 | -21 | -21 | -20 | N/A |
| 3/31/2022 | 24 | -19 | -18 | -17 | N/A |
| 12/31/2021 | 22 | -17 | -19 | -19 | N/A |
| 9/30/2021 | 20 | -16 | -18 | -17 | N/A |
| 6/30/2021 | 19 | -17 | -14 | -14 | N/A |
| 3/31/2021 | 17 | -16 | -15 | -14 | N/A |
| 12/31/2020 | 16 | -16 | -15 | -14 | N/A |
| 9/30/2020 | 16 | -15 | -16 | -15 | N/A |
| 6/30/2020 | 15 | -18 | -18 | -17 | N/A |
| 3/31/2020 | 15 | -19 | -18 | -17 | N/A |
| 12/31/2019 | 14 | -18 | -15 | -15 | N/A |
| 12/31/2018 | 11 | -24 | -20 | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AUGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AUGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AUGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AUGX's revenue (20.6% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: AUGX's revenue (20.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AUGX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/03 00:56 |
| End of Day Share Price | 2024/10/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Augmedix, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Sutherland | Benchmark Company |
| Yuan Zhi | B. Riley Securities, Inc. |
| Elizabeth Anderson | Evercore ISI |